medigraphic.com
Instituto Nacional de Salud Pública

2015, Number S2

<< Back Next >>

salud publica mex 2015; 57 (S2)

AIDS-related early mortality in Mexico between 2008 and 2012

Silverman-Retana O, Bautista-Arredondo S, Serván-Mori E, Lozano R

Language: Spanish
References: 16
Page: 119-126
PDF size: 233.50 Kb.


ABSTRACT

Objective. To describe the distribution of AIDS-related mortality according to the time of occurrence since entry to the System for the Administration, Logistics and Surveillance of Antiretrovirals (SALVAR, in Spanish), among users of Ministry of Health facilities in Mexico. Materials and methods. Descriptive analysis of AIDS mortality and the related clinical and demographic profile of 41 847 patients registered in SALVAR. Results. 3 195 patients (8.1%) died within the study period, 59% of these deaths occurred within six months after treatment initiation. Among those patients, 87.3% were diagnosed late, given their CD4 levels (CD- 4cel‹200 cel/ml3). Conclusion. Our results underscore the need to strengthen programs aimed to increase opportune HIV diagnosis and linkage to care, as a key component of universal access policy to antiretroviral treatment in Mexico.


REFERENCES

  1. Murray CJL, Ortblad KF, Guinovart C, Lim SS, Wolock TM, Roberts DA, et al. Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2014;6736(14):1-66.

  2. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuerher J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-860.

  3. Joint United Nations Programme on HIV/AIDS. UNAIDS Report on the global AIDS epidemic 2013. Geneva, Switzerland: UNAIDS, 2013.

  4. Gonzalez MA, Martin L, Munoz S, Jacobson JO. Patterns, trends and sex differences in HIV/AIDS reported mortality in Latin American countries: 1996-2007. BMC Public Health 2011;11(1):605. doi: 10.1186/1471- 2458-11-605.

  5. Anglaret X, Minga A, Gabillard D, Ouassa T, Messou E, Morris B, et al. AIDS and non-AIDS morbidity and mortality across the spectrum of CD4 cell counts in HIV-infected adults before starting antiretroviral therapy in Cote d’Ivoire. Clin Infect Dis 2012;54 (5):714-723. doi:10.1093/cid/cir898.

  6. Grinsztejn B, Veloso VG, Friedman RK, Moreira RI, Luz PM, Campos DP, et al. Early mortality and cause of deaths in patients using HAART in Brazil and the United States. AIDS 2013;23(16):2107-2114. doi:10.1097/ QAD.0b013e32832ec494.Early.

  7. Ingle SM, May MT, Gill MJ, Mugavero MJ, Lewden C, Abgrall S, et al. Impact of risk factors for specific causes of death in the first and subsequent years of antiretroviral therapy among HIV-infected patients. Clin Infect Dis 2014;59(2):287-297. doi:10.1093/cid/ciu261.

  8. Borrell C, Rodríguez-Sanz M, Pasarín MI, Brugal MT, García-de-Olalla P, Marí-Dell´Olmo M, et al. AIDS mortality before and after the introduction of highly active antiretroviral therapy: does it vary with socioeconomic group in a country with a national health system? Eur J Public Health 2006;16(6):601-608. doi:10.1093/eurpub/ckl062.

  9. The Antiretoviral Cohort Collaboration. Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries. Int J Epidemiol 2009;38(6):1624-1633. doi:10.1093/ije/dyp306.

  10. The Caribbean Central and South America Network for HIV Research (Ccasanet) Collaboration, of the International Epidemiologic Databases to Evaluate AIDS (IEDEA) Program. Mortality during the first year of potent antiretroviral therapy in HIV-1-infected patients in 7 sites throughout Latin America and the Caribbean. J Acquir Immune Defic Syndr 2010;51(5):615-623. doi:10.1097/QAI.0b013e3181a44f0a.Mortality.

  11. Hernández-Ávila JE, Palacio-Mejía LS, Hernández-Romieu A, Bautista- Arredondo S, Sepúlveda Amor J, Hernández-Ávila M, et al. Effect of universal access to antiretroviral therapy on HIV/AIDS mortality in Mexico 1990- 2011. JAIDS 2015 [consultado en diciembre de 2013]. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/25886921.

  12. Cahuana-Hurtado L, Chilian-Herrera O, Bautista-Arredondo S, Contreras- Loya D, Franco-Marina F, González-Vilchis JJ, Lozano R. Corrección de la mala clasificación de las muertes por sida en México. Análisis retrospectivo de 1983 a 2012. Salud Publica Mex 2015;57 supl 2:S142-S152.

  13. Córdova-Villalobos JA, Ponce-de León Rosales S, Valdespino JL, eds. 25 años de sida en México. Logros, desaciertos y retos. 2da ed. México: Instituto Nacional de Salud Pública, 2009.

  14. Secretaría de Salud, Subsecretaría de Prevención y Promoción de la Salud, Centro Nacional para la Prevención y el Control del VIH y el Sida. Sistema de Administración y Logística de ARV (SALVAR) [base de datos en Internet]. México: Censida, 2006 [consultado en diciembre de 2013]. Disponible en: http:/www.salvar.salud.gob.mx.

  15. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva, Switzerland: WHO, 2013.

  16. Crabtree-Ramírez B, Caro-Vega Y, Shepherd BE, Wehbe F, Cesar C, Cortés C, et al. Cross-sectional analysis of late HAART initiation in Latin America and the Caribbean: late testers and late presenters. PLoS One 2011;6(5):e20272. doi:10.1371/journal.pone.0020272.




2020     |     www.medigraphic.com